Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covis Pharma

http://covispharma.com

Latest From Covis Pharma

Accelerated Approval Withdrawals: Will Non-Oncology Indications Stop ‘Dangling’ In 2024?

While at least 25 accelerated approval cancer indications or drugs have been pulled or requested withdrawn since 2020, there has not yet been a similar concerted regulatory effort in the non-oncology space despite a large number of products with overdue postmarketing requirements.

Pink Sheet Perspectives Review Pathway

Preterm Birth Patients Sought By US FDA As Meeting On Treatment Development Looms

With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.

Women's Health Research & Development

US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner

When Janet Woodcock retires early next year, Namandjé Bumpus will take over as No. 2 in command at the FDA. Since joining the agency in 2022 from Johns Hopkins, her profolio has included health disparities, cosmetics, and drug review disputes.

FDA Leadership

US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner

When Janet Woodcock retires early next year, Namandjé Bumpus will take over as No. 2 in command at the FDA. Since joining the agency in 2022 from Johns Hopkins, her profolio has included health disparities, cosmetics, and drug review disputes.

FDA Leadership
See All

Company Information

UsernamePublicRestriction

Register